These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36185140)

  • 1. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
    Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
    Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.
    Wang JL; Meng WJ; Hu N; Liu JY
    Front Immunol; 2024; 15():1349033. PubMed ID: 38989283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
    Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
    Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
    Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
    Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
    Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
    Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.
    Lan Y; Zhao J; Zhao F; Li J; Li X
    Front Oncol; 2024; 14():1338661. PubMed ID: 38952555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
    Fan S; He L; Sang D
    Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.
    Wang J; Liu Y; Zhang Q; Li W; Feng J; Wang X; Fang J; Han Y; Xu B
    Cancer Commun (Lond); 2024 Jul; 44(7):833-851. PubMed ID: 38940019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
    Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
    Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
    Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
    Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.
    Hu Y; Chen F; Sun S; Xv L; Wang X; Wang M; Zhao S; Zhao Z; Li M
    Front Oncol; 2024; 14():1312634. PubMed ID: 38344201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.